Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?

David Nolan1

  • 1Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Western Australia, Australia. David.Nolan@health.wa.gov.au

Drug Safety
|December 7, 2005
PubMed
Summary

Antiretroviral therapy can cause lipodystrophy, including pathological fat loss (lipoatrophy) and metabolic issues. Nucleoside reverse transcriptase inhibitors like stavudine are linked to lipoatrophy, while protease inhibitors and HIV status influence metabolic complications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Obstetric Management and Outcomes for Women Living With HIV in Western Australia: A 30 Year Review.

The Australian & New Zealand journal of obstetrics & gynaecology·2026
Same author

The running performance characteristics of U16 and U18 inter-county Ladies Gaelic Football players: An analysis across halves, playing positions, and age grades.

PloS one·2026
Same author

Correction: VEXAS: A review of current understandings and emerging treatment strategies.

Frontiers in immunology·2026
Same author

The impact of accumulating immune adaptation in circulating strains of HIV-1.

HIV medicine·2026
Same author

Experimental investigation of the microstructure and mechanics of human middle cerebral arteries.

Journal of the mechanical behavior of biomedical materials·2026
Same author

Predicting a Successful Attempt in Raw Powerlifting. A Nonlinear Mixed Logistic Regression Analysis.

Journal of strength and conditioning research·2025

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Endocrinology

Background:

  • Antiretroviral therapy (ART) is crucial for managing HIV infection but can lead to long-term toxicities.
  • Lipodystrophy, encompassing lipoatrophy (pathological fat loss) and metabolic complications, is a significant concern in patients on ART.
  • Understanding drug-specific risks and contributing factors is essential for optimizing HIV treatment.

Purpose of the Study:

  • To clarify the contribution of specific antiretroviral drugs to lipodystrophy complications.
  • To elucidate the etiological basis of metabolic complications associated with ART.
  • To evaluate the safety profile of non-nucleoside reverse transcriptase inhibitors (NNRTIs) regarding lipodystrophy.

Main Methods:

  • Review and synthesis of accumulated data over the past 6 years on ART-associated toxicities.

Related Experiment Videos

  • Analysis of the association between specific nucleoside reverse transcriptase inhibitors (NRTIs) and lipoatrophy.
  • Investigation of factors modulating the risk of metabolic complications, including lifestyle, HIV status, and protease inhibitors.

    • Main Results:

    • Lipoatrophy is strongly associated with stavudine and, to a lesser extent, zidovudine (NRTIs).
    • Metabolic complications are complex, influenced by lifestyle factors, HIV disease status, and HIV protease inhibitors.
    • Licensed NNRTIs (efavirenz, nevirapine) demonstrate a favorable safety profile concerning lipodystrophy.

    Conclusions:

    • Specific NRTIs, particularly stavudine, are linked to lipoatrophy, necessitating careful drug selection.
    • Metabolic complications are multifactorial, requiring consideration of patient lifestyle, HIV status, and drug class.
    • While NNRTIs have a favorable lipodystrophy profile, their individual toxicity profiles must be monitored in HIV treatment.